CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

NCT03275493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
CD19 Positive
Relapse
Refractory

Interventions

BIOLOGICAL: CD19 CAR-T cells
BIOLOGICAL: CD19 CAR-T cells with CRS suppression technology

Sponsor

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Collaborators

[object Object]